The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
What is the moon phase today? Today, Feb. 3, 2025, the moon is 5 days old, in the waxing crescent phase of its lunar cycle. It is 32% illuminated. Moon phases reveal the passage of time in the ...
Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback